Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study.

Jocelyne Just Celine ThonnelierMelisande Bourgoin-HeckLaurence MalaMathieu Molimard Marc Humbertnull null

Published in: Journal of asthma and allergy (2021)

This post-hoc analysis of the STELLAIR study shows that omalizumab is beneficial for all SAA patients and especially for patients with multiple AC or AD. In patients with ≥3 AC, omalizumab also improved AC outcomes.

Keyphrases

randomized controlled trial
systematic review
ejection fraction
type diabetes
prognostic factors
early onset
adipose tissue
metabolic syndrome
lung function
skeletal muscle
air pollution
weight loss